News
Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback